Literature DB >> 2177165

Differential interactions of cholecystokinin and FLFQPQRF-NH2 with mu and delta opioid antinociception in the rat spinal cord.

D S Magnuson1, A F Sullivan, G Simonnet, B P Roques, A H Dickenson.   

Abstract

An in vivo preparation of the rat spinal cord was used to investigate the electrophysiological actions of two non-opioid peptides, cholecystokinin (CCK8) and FLFQPQRF-NH2 (FMRFamide-like peptide) applied intrathecally. These compounds were examined alone and as a pretreatment before DAGO, a mu opioid agonist, and DSTBULET, a delta opioid agonist, both which selectively reduce C-fibre evoked dorsal horn neurone activity elicited by transcutaneous electrical stimulation. Given alone, CCK8 (1 microgram) elicited a modest enhancement of C-fibre induced activity which returned to control levels after 20 min, while FLFQPQRF-NH2 (10 micrograms) had no significant effect on C-fibre evoked firing. As a pretreatment, however, both peptides selectively prevented the inhibition of C-fibre evoked activity normally resulting from intrathecal DAGO, while having no effect on that resulting from DSTBULET. Further, CCK8 enhanced the facilitation of C-fibre evoked firing normally observed with low doses of DAGO. These data indicate that the anti-opioid roles suggested for CCK8 and FLFQPQRF-NH2 may be specific for neural elements utilizing the mu opioid receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2177165     DOI: 10.1016/0143-4179(90)90065-7

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  9 in total

1.  Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.

Authors:  Yeon Sun Lee; Richard S Agnes; Hamid Badghisi; Peg Davis; Shou-wu Ma; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

Review 2.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

3.  A locus and mechanism of action for associative morphine tolerance.

Authors:  J M Mitchell; A I Basbaum; H L Fields
Journal:  Nat Neurosci       Date:  2000-01       Impact factor: 24.884

Review 4.  Association of enkephalin catabolism inhibitors and CCK-B antagonists: a potential use in the management of pain and opioid addiction.

Authors:  B P Roques; F Noble
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

5.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

Authors:  L C Stanfa; A H Dickenson
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

6.  Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain.

Authors:  F Noble; M Derrien; B P Roques
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  Role of opioid receptors in the spinal antinociceptive effects of neuropeptide FF analogues.

Authors:  C Gouardères; K Jhamandas; M Sutak; J M Zajac
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  Dexamethasone-induced selective inhibition of the central mu opioid receptor: functional in vivo and in vitro evidence in rodents.

Authors:  S Pieretti; A Di Giannuario; M R Domenici; S Sagratella; A Capasso; L Sorrentino; A Loizzo
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 9.  Crosstalk between Opioid and Anti-Opioid Systems: An Overview and Its Possible Therapeutic Significance.

Authors:  Ewa Gibula-Tarlowska; Jolanta H Kotlinska
Journal:  Biomolecules       Date:  2020-09-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.